These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22336482)

  • 1. [Prostate Specific Antigen (PSA), yet how much damage?].
    Braillon A; Hill C; Dubois G
    Presse Med; 2012 May; 41(5):482-5. PubMed ID: 22336482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of total PSA and free PSA prescriptions.
    Lamy PJ; Brouillet JP; Bermont L; Fouillet G; Loric S
    Ann Biol Clin (Paris); 2018 Dec; 76(6):659-663. PubMed ID: 30543191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].
    Cepeda Piorno J; Rivas del Fresno M; Fuente Martín E; González García E; Muruamendiaraz Fernández V; Fernández Rodríguez E
    Arch Esp Urol; 2005 Jun; 58(5):403-11. PubMed ID: 16078781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen or human kallikrein 3? Recent developments.
    Diamandis EP
    Tumour Biol; 1998; 19(2):65-7; discussion 67-8. PubMed ID: 9486557
    [No Abstract]   [Full Text] [Related]  

  • 5. PSA testing for men at average risk of prostate cancer.
    Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Punishing Physicians for PSA Screening.
    Gomella LG
    Can J Urol; 2015 Dec; 22(6):8042. PubMed ID: 26688130
    [No Abstract]   [Full Text] [Related]  

  • 7. [Use of prostatic specific antigen in primary care (PSA)].
    Panach-Navarrete J; Gironés-Montagud A; Sánchez-Cano E; Doménech-Pérez C; Martínez-Jabaloyas JM
    Semergen; 2017 Apr; 43(3):189-195. PubMed ID: 27344583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
    Bourel M; Ardaillou R;
    Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 10. Navigating Prostate Cancer Screening in the Real World of Primary Care: The Mirage and the Quicksand.
    Mathew P; Hachem H; Han P
    JAMA Oncol; 2018 Apr; 4(4):453-454. PubMed ID: 29470576
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate cancer screening.
    Roetzheim RG; Herold AH
    Prim Care; 1992 Sep; 19(3):637-49. PubMed ID: 1384077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The level of evidence for the use of biomarkers in the early detection of prostate cancer].
    Lamy PJ; Gauchez AS; Salomon L; Haugh M; Ceraline J; Fulla Y; Georges A; Larré S; Loric S; Luporsi E; Martin PM; Mazerolles C; Molinié V; Mongiat-Artus P; Piffret J; Thuillier F; Perrin P; Rebillard X;
    Ann Biol Clin (Paris); 2016; 74(2):227-32. PubMed ID: 27029727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate carcinoma: clarification through clinical insight and molecular diagnostics.
    Meyers FJ; DeVere White RW
    West J Med; 1998 Jun; 168(6):525. PubMed ID: 9655997
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline.
    Tikkinen KAO; Dahm P; Lytvyn L; Heen AF; Vernooij RWM; Siemieniuk RAC; Wheeler R; Vaughan B; Fobuzi AC; Blanker MH; Junod N; Sommer J; Stirnemann J; Yoshimura M; Auer R; MacDonald H; Guyatt G; Vandvik PO; Agoritsas T
    BMJ; 2018 Sep; 362():k3581. PubMed ID: 30185545
    [No Abstract]   [Full Text] [Related]  

  • 15. PSA screening for prostate cancer: the current controversy.
    de Koning HJ; Schröder FH
    Ann Oncol; 1998 Dec; 9(12):1293-6. PubMed ID: 9932158
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians].
    Giménez N; Filella X; Gavagnach M; Allué JA; Pedrazas D; Ferrer F;
    Semergen; 2018 Sep; 44(6):409-419. PubMed ID: 29574008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seniority of primary care physicians is associated with a decrease in PSA ordering habits in the years surrounding the United States Preventative Services Task Force recommendation against PSA screening.
    Hutchinson R; Singla N; Akhtar A; Haridas J; Bhat D; Roehrborn C; Lotan Y
    Urol Oncol; 2018 Nov; 36(11):500.e21-500.e27. PubMed ID: 30241954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
    Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.